PureTech Health/PRTC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About PureTech Health

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Ticker

PRTC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bharatt Chowrira

Employees

111

Headquarters

Boston, United States

PureTech Health Metrics

BasicAdvanced
$806M
Market cap
-
P/E ratio
-$1.66
EPS
1.25
Beta
-
Dividend rate
$806M
1.24848
$34.00
$17.08
1.7K
7.309
3.893
4.979
-34.79%
-5.16%
-8.58%
-5.90%
68.673
1.572
-36.83%
-255.18%
16.78%

What the Analysts think about PureTech Health

Analyst Ratings

Majority rating from 1 analysts.
Buy

PureTech Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-806.45% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$3.1M
-63.53%
Net income
-$25M
13.64%
Profit margin
-806.45%
211.59%

PureTech Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 335.29%
QuarterlyAnnual
Q2 22
Q4 22
Actual
-$1.00
-$0.80
Expected
-$2.75
$0.34
Surprise
-63.57%
-335.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PureTech Health stock?

PureTech Health (PRTC) has a market cap of $806M as of June 18, 2024.

What is the P/E ratio for PureTech Health stock?

The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 0 as of June 18, 2024.

Does PureTech Health stock pay dividends?

No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next PureTech Health dividend payment date?

PureTech Health (PRTC) stock does not pay dividends to its shareholders.

What is the beta indicator for PureTech Health?

PureTech Health (PRTC) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the PureTech Health stock price target?

The target price for PureTech Health (PRTC) stock is $58, which is NaN% below the current price of $. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PureTech Health stock

Buy or sell PureTech Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing